| Document Date: 2015-04-22 23:39:46
Open Document File Size: 162,32 KBShare Result on Facebook
Company Indirect Comp / Parallel Group Safety / Plac / Efficacy / Arm Parallel Group / Randomised / Double-Blind / Internal / Doubleblind / Study A Phase II / Boehringer Ingelheim Pty Ltd / / Event FDA Phase / Product Issues / / IndustryTerm Diabetes care / treatment algorithm / / MedicalCondition bacteriuria and urinary tract infection / diabetes / diabetes mellitus / urinary tract infections / inflammation / infections / inhibitor Diabetes / II diabetes / / Organization Advisory Committee on Prescription Medicines / Association of Physicians of India / Boehringer Ingelheim Authority / / Product glipizide / glucagon / glimepiride / ORAL TABLET / Meeting 5.4 EMPAGLIFLOZIN / BI / BMS-512148 / glycemic control / CT-004 / Glycaemic Control / BID / empagliflozin / / Technology Pharmacokinetics / treatment algorithm / 139 Diabetes Technology / 2014 PBAC Meeting Trial ID Protocol / PBS-subsidised treatment algorithm / dapagliflozin Trial ID Protocol / /
SocialTag |
Microsoft Word - BoehringerempagliflozinPSD final.docx